Physician profile
Tobias Pusch
NPI 1811189632
$207,520.39
in general payments reported to CMS, 2019-2025
11 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,919 · 2021: $8,900 · 2022: $22K · 2023: $28K · 2024: $48K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $29K · Consulting Fee: $12K · Food and Beverage: $7,784 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,115.00 |
| Travel and Lodging | $29,032.44 |
| Consulting Fee | $12,430.00 |
| Food and Beverage | $7,783.72 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $106,135.18 | 2019-2025 | Biktarvy, Veklury, Yeztugo |
| Viiv Healthcare Company | $98,614.83 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Seqirus USA INC | $2,108.64 | 2022-2024 | |
| Allergan, INC. | $274.68 | 2019-2020 | |
| Shionogi INC | $99.73 | 2022 | |
| Merck Sharp & Dohme LLC | $82.18 | 2019 | |
| Janssen Products, Lp | $81.58 | 2019 | |
| Glaxosmithkline, LLC. | $43.20 | 2025 | Blujepa, Brexafemme |
| Pfizer INC. | $41.45 | 2024 | |
| Abbvie INC. | $20.00 | 2023 | |
| Bavarian Nordic A/S | $18.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobias Pusch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.